Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s00280-023-04593-w.pdf
Reference8 articles.
1. Hortlund M, Arroyo Muhr LS, Storm H et al (2017) Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer 140(5):1091–1101
2. Yasuda H, Yasuda M, Komatsu N (2021) Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review. Cancer Sci 112(7):2607–2624
3. Zhao B, Chen R, O’Connor OA et al (2016) Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol 82(3):696–705
4. Nanni L, Pellegrini C, Stefoni V et al (2019) Successful employment of brentuximab vedotin in a patient undergoing hemodialysis: the first real-life experience. Clin Lymphoma Myeloma Leuk 19(11):e595–e596
5. Kinoshita T, Hatake K, Yamamoto K et al (2021) Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. Jpn J Clin Oncol 51(1):70–77
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3